Physician profile
Ruth E Fowler
NPI 1639339179
$373.19
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $95.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $116.32 | 2021-2022 | |
| Lilly USA, LLC | $73.11 | 2021 | |
| Glaxosmithkline, LLC. | $33.91 | 2021-2022 | |
| Novo Nordisk INC | $32.60 | 2021 | |
| Ucb, INC. | $30.75 | 2021 | |
| Merck Sharp & Dohme LLC | $18.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.10 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.91 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.88 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.15 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.22 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.